Lead Product(s) : Sodium Tungstate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oxolife’s Oral Drug Increases IVF and ICSI Success Rates, Data Presented at ESHRE
Details : OXO-001 (sodium tungstate) is a first-in-class, non-hormonal drug that enhances embryo implantation. It is taken as a tablet twice daily, starting one menstrual cycle before embryo transfer.
Product Name : OXO-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2024
Lead Product(s) : Sodium Tungstate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
